Global Cell And Gene Therapy Supply Chain Software Market, a rapidly growing sector, Size is valued at USD 269.3 Mn in 2024 and is predicted to reach USD 982.1 Mn by the year 2034 at a 14.0% CAGR during the forecast period for 2025-2034.
The recent commercial success of the cell and gene therapy market is to be seen due to their ability to provide the desired therapeutic benefits and developers' capacity to meet all supply chain needs efficiently. The cell & gene therapy supply chain is comparatively more complex than the conventional pharmaceutical supply chain, directing to the temperature sensitivity as well as the uniqueness of some products. As a result, there are various risks regarding process redundancy, including possible operational reluctance. Therapy developers must take care of these capacity scheduling concerns, process delays leading to capital loss, and delivery / tracking-related issues.
In recent years, the field of medicine has seen some ground-breaking developments with the emergence of Cell and Gene Therapies (CGT). CGT is rapidly altering the therapy arena, promising long-term patient maintenance or cure. To do so effectively, biopharma companies must solve the complexities of their unique supply chain. Specific supply chain capabilities are necessary to address the unique complexity of CGT products' high-touch and personalized supply chain.
The Cell & Gene Therapy Supply Chain Software market, which has experienced significant growth due to advancements in medical technology and increased demand for personalized treatments, was not immune to the effects of the COVID-19 pandemic. The pandemic disrupted the supply chain, causing delays in manufacturing, distribution, and clinical trials. This led to increased interest in supply chain software solutions to improve efficiency, visibility, and agility.
In the cell & gene therapy supply chain software market, segmentation includes process component, type of software, mode of deployment, type of end-user, and scale of operation. The market is segmented based on process components, such as sample collection and processing components, manufacturing domains, logistics components, and patient identification and treatment follow-up components. By Type of Software, the market is segmented by enterprise manufacturing system, laboratory information management system, inventory management system, cell orchestration platform, quality management system, logistics management system, patient management system (PMS). By mode of deployment, the market is segmented by on-premises deployment, cloud-based deployment. By Type of end-user, the market is segmented by pharmaceutical companies, cell therapy labs, hospitals / medical centers, research institutes / biobanks. By Scale of operation, the market is segmented by clinical scale, commercial scale.
In the Cell & Gene Therapy Supply Chain Software Market, the Sample Collection and Processing Component is a major contributor due to its critical role in ensuring product quality and patient safety. This component involves managing the collection, transportation, and processing of biological samples in therapy production. Efficient sample management is essential for maintaining product integrity, complying with regulatory requirements, and minimizing risks of contamination or degradation. Software solutions in this area provide features for sample tracking, inventory management, chain of custody documentation, and cumulation with laboratory information management systems (LIMS), enhancing overall supply chain efficiency and reliability.
The Laboratory Information Management System (LIMS) is experiencing rapid growth due to its pivotal role in managing complex data in laboratories. With technological enhancements and the increasing demand for precision medicine and personalized therapies, laboratories are creating vast amounts of data that require efficient organization, analysis, and storage. LIMS automates workflows, tracks samples, manages data and ensures compliance with regulations. Its ability to smoothen processes, improve data accuracy, and enhance collaboration among researchers and clinicians has fueled its adoption across various industries, including healthcare, pharmaceuticals, biotechnology, and environmental science, contributing to its rapid growth.
The North America Cell and Gene Therapy Supply Chain Software Market commands a significant revenue share due to several key factors. Firstly, North America is a hub for the biotechnology and pharmaceutical industries, with a robust ecosystem of companies specializing in cell and gene therapy research, development, and manufacturing. Major cities like Boston, San Francisco, and San Diego are home to numerous biotech firms and research institutions, fostering innovation and collaboration in the field.
This can be related to the increasing R&D investments, partnership agreements, and funding gained by different therapy developers to develop novel cell and gene therapies. Moreover, the region benefits from a well-established healthcare infrastructure and regulatory framework supporting advanced therapies' development and commercialization. Concerned authorities, for instance, the Food and Drug Administration, provide clear guidelines and pathways for the approval of cell and gene therapies, instilling confidence in investors and manufacturers.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 269.3 Mn |
| Revenue Forecast In 2034 | USD 982.1 Mn |
| Growth Rate CAGR | CAGR of 14.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Process Component, Type Of Software, Mode Of Deployment, Type Of End-User, And Scale Of Operation |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Azenta Life Sciences, NMDP Bio-Therapies, Care DX, BioLife Solutions, Biocair, LabVantage Solutions, Lonza, TraceLink, TrakCel, Veeva Systems, Emerson, Cryoport, Marken, MasterControl, Steiner, Siemens, Stafa Cellular Therapy, QuickSTAT, STEMSOFT Software, TECHNIDATA and Thermo Fisher Scientific. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Cell & Gene Therapy Supply Chain Software Market By Process Component-
Cell & Gene Therapy Supply Chain Software Market By Type of Software-
Cell & Gene Therapy Supply Chain Software Market By Mode of Deployment-
Cell & Gene Therapy Supply Chain Software Market By Type of End-User-
Cell & Gene Therapy Supply Chain Software Market By Scale of Operation-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Supply Chain Software Market Snapshot
Chapter 4. Global Cell and Gene Therapy Supply Chain Software Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Process Component Estimates & Trend Analysis
5.1. by Process Component & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Process Component:
5.2.1. Sample Collection and Processing Component
5.2.2. Manufacturing Component
5.2.3. Logistics Component
5.2.4. Patient Identification and Treatment Follow-up Component
Chapter 6. Market Segmentation 2: by Type of Software Estimates & Trend Analysis
6.1. by Type of Software & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Software:
6.2.1. Enterprise Manufacturing System (EMS)
6.2.2. Laboratory Information Management System (LIMS)
6.2.3. Inventory Management System (IMS)
6.2.4. Cell Orchestration Platform (COP)
6.2.5. Quality Management System (QMS)
6.2.6. Logistics Management System (LMS)
6.2.7. Patient Management System (PMS)
Chapter 7. Market Segmentation 3: by Mode of Deployment Estimates & Trend Analysis
7.1. by Mode of Deployment & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Deployment:
7.2.1. On-premises Deployment
7.2.2. Cloud-based Deployment
Chapter 8. Market Segmentation 4: by Scale of Operation Estimates & Trend Analysis
8.1. by Scale of Operation & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Scale of Operation:
8.2.1. Clinical Scale
8.2.2. Commercial Scale
Chapter 9. Market Segmentation 5: by End-User Estimates & Trend Analysis
9.1. by End-User & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-User:
9.2.1. Pharmaceutical Companies
9.2.2. Cell Therapy Labs
9.2.3. Hospitals / Medical Centers
9.2.4. Research Institutes / Biobanks
Chapter 10. Cell and Gene Therapy Supply Chain Software Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component,2021-2034
10.1.2. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.1.3. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.1.4. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.1.5. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.1.6. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.2.2. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.2.3. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.2.4. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.2.5. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.2.6. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.3.2. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.3.3. Asia-Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.3.4. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.3.5. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3.6. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.4.2. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.4.3. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.4.4. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.4.5. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4.6. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.5.2. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.5.3. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.5.4. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.5.5. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5.6. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Azenta Life Sciences
11.2.2. Biocair
11.2.3. BioLife Solutions
11.2.4. CareDx
11.2.5. Cryoport
11.2.6. Lonza
11.2.7. NMDP BioTherapies
11.2.8. TraceLink
11.2.9. TrakCel
11.2.10. Veeva Systems
11.2.11. Emerson
11.2.12. LabVantage Solutions
11.2.13. Marken
11.2.14. MasterControl
11.2.15. QuickSTAT
11.2.16. Siemens
11.2.17. Stafa Cellular Therapy
11.2.18. Steiner
11.2.19. STEMSOFT Software
11.2.20. TECHNIDATA
11.2.21. Thermo Fisher Scientific
Cell & Gene Therapy Supply Chain Software Market By Process Component-
Cell & Gene Therapy Supply Chain Software Market By Type of Software-
Cell & Gene Therapy Supply Chain Software Market By Mode of Deployment-
Cell & Gene Therapy Supply Chain Software Market By Type of End-User-
Cell & Gene Therapy Supply Chain Software Market By Scale of Operation-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-